Shares of Furiex Pharmaceuticals (NASDAQ: FURX) exploded today, up 145% as the company released data that its drug treating a form of IBS that results in diarrhea passed its phase 3 trials, soundly beating a placebo at the higher dosing.

In this video, Motley Fool health-care analyst David Williamson discusses whether or not he thinks the drug will be approved and what the potential market size could be, and looks at just how high this stock could go.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.